Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

NKTR

Nektar Therapeutics

Dec 13 • 04:00PM ET

1.01

Dollar change +0.01
Percentage change 1.00	%

Healthcare • Biotechnology • USA • NASD

Peers: AMGN BIIB VRTX GILD REGN INCY IONS SRPT EXEL NBIX

| Held by: VTI IWM VXF IWN VTWO SCHA VHT PRFZ IWC FESM

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.84	Insider Own	3.38%	Shs Outstand	184.46M	Perf Week	-0.98%
Market Cap	188.16M	Forward P/E	-	EPS next Y	-0.74	Insider Trans	-0.91%	Shs Float	178.22M	Perf Month	-21.09%
Income	-168.30M	PEG	-	EPS next Q	-0.13	Inst Own	74.38%	Short Float	2.49%	Perf Quarter	-20.47%
Sales	93.14M	P/S	2.02	EPS this Y	51.45%	Inst Trans	3.98%	Short Ratio	2.63	Perf Half Y	-13.68%
Book/sh	0.27	P/B	3.81	EPS next Y	-5.38%	ROA	-44.87%	Short Interest	4.44M	Perf Year	102.45%
Cash/sh	1.31	P/C	0.77	EPS next 5Y	-7.30%	ROE	-161.63%	52W Range	0.46 - 1.93	Perf YTD	78.76%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-72.09%	52W High	-47.61%	Beta	0.57
Dividend TTM	-	Quick Ratio	4.24	Sales past 5Y	-20.42%	Gross Margin	67.80%	52W Low	121.98%	ATR (14)	0.07
Dividend Ex-Date	-	Current Ratio	4.24	EPS Y/Y TTM	46.09%	Oper. Margin	-145.91%	RSI (14)	37.99	Volatility	5.03% 6.92%
Employees	137	Debt/Eq	4.22	Sales Y/Y TTM	5.53%	Profit Margin	-180.70%	Recom	2.50	Target Price	4.16
Option/Short	Yes / Yes	LT Debt/Eq	3.78	EPS Q/Q	26.42%	Payout	-	Rel Volume	1.22	Prev Close	1.00
Sales Surprise	25.81%	EPS Surprise	9.55%	Sales Q/Q	-0.08%	Earnings	Nov 07 AMC	Avg Volume	1.69M	Price	1.01
SMA20	-3.76%	SMA50	-17.10%	SMA200	-19.95%	Trades		Volume	2,058,410	Change	1.00%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-10-24	Initiated	H.C. Wainwright	Buy	$6.50
Nov-04-24	Initiated	Piper Sandler	Overweight	$7
Sep-30-24	Resumed	BTIG Research	Buy	$4
Jun-28-24	Initiated	Rodman & Renshaw	Buy	$2
Nov-20-23	Resumed	JP Morgan	Underweight
Nov-09-23	Upgrade	TD Cowen	Market Perform → Outperform
May-10-23	Upgrade	Jefferies	Underperform → Hold	$1.50 → $1
Feb-24-23	Downgrade	Jefferies	Hold → Underperform	$3.20 → $1.50
Aug-08-22	Downgrade	JP Morgan	Neutral → Underweight
May-31-22	Resumed	Jefferies	Hold	$12 → $4
Apr-18-22	Downgrade	Goldman	Neutral → Sell	$3
Mar-15-22	Downgrade	Mizuho	Buy → Neutral	$35 → $8
Mar-15-22	Downgrade	Cowen	Outperform → Market Perform
Mar-14-22	Downgrade	William Blair	Outperform → Mkt Perform
Mar-14-22	Downgrade	Stifel	Buy → Hold	$24 → $5
Mar-14-22	Downgrade	BTIG Research	Buy → Neutral
Mar-14-22	Downgrade	BofA Securities	Neutral → Underperform	$18 → $6
Mar-09-22	Upgrade	Oppenheimer	Perform → Outperform	$21
Nov-08-21	Upgrade	The Benchmark Company	Hold → Buy	$20
Sep-10-21	Initiated	BofA Securities	Neutral	$18

Show Previous Ratings

Dec-07-24 12:00PM	Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting (PR Newswire)
Nov-18-24 03:30PM	Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence (PR Newswire)
Nov-08-24 02:30AM	Nektar Therapeutics (NKTR) Q3 2024 Earnings Call Highlights: Strategic Moves and Financial Outlook (GuruFocus.com)
Nov-07-24 05:40PM	Nektar Therapeutics (NKTR) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:36PM	Nektar: Q3 Earnings Snapshot (Associated Press Finance)
04:15PM	Loading…
04:15PM	Nektar Therapeutics Reports Third Quarter 2024 Financial Results (PR Newswire)
10:15AM	Nektar and Collaborators Present Late-breaking Results from Phase 2 Study of NKTR-255 for the Treatment of Radiation Induced Lymphopenia in Locally Advanced Non-Small Cell Lung Cancer Patients at Society for Immunotherapy of Cancer (SITC) Annual Meeting (PR Newswire)
Nov-06-24 06:00PM	Nektar Therapeutics to Participate in Upcoming Investor Conferences (PR Newswire)
Nov-05-24 10:34AM	Nektar Therapeutics to sell Alabama facility to Ampersand (Pharmaceutical Technology) +5.26%
Nov-04-24 01:44PM	Eczema Drug Developer Nektar Gains Analyst Confidence With 400% Upside Potential (Benzinga) +8.13%
08:30AM	Nektar Announces Definitive Agreement with Ampersand Capital Partners to Sell Its Commercial PEGylation Reagent Manufacturing Business in Alabama (PR Newswire)
Oct-31-24 06:00PM	Nektar to Announce Financial Results for the Third Quarter 2024 on Thursday, November 7, 2024, After Close of U.S.-Based Financial Markets (PR Newswire)
Oct-29-24 09:00AM	Nektar Announces Publication in Nature Communications of Results from Phase 1b Studies of Rezpegaldesleukin in Two Inflammatory Skin Diseases (PR Newswire) -6.62%
Oct-17-24 12:07PM	Nektar Announces Publication in Blood of Phase 1 Data for Novel IL-15 Agonist NKTR-255 in Combination with Autologous CD19-22 CAR-T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia (PR Newswire) +5.07%
Sep-25-24 03:30AM	Nektar Therapeutics Announces Multiple Presentations for Rezpegaldesleukin at EADV 2024 (PR Newswire)
09:00AM	Loading…
Sep-03-24 09:00AM	Nektar Management to Present at Upcoming Investor Conferences (PR Newswire)
Aug-13-24 12:00PM	What Makes Nektar (NKTR) a New Buy Stock (Zacks)
Aug-09-24 10:58AM	Nektar's (NKTR) Q2 Earnings Lag Estimates, Revenues Top (Zacks) -8.26%
Aug-08-24 05:55PM	Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:49PM	Nektar: Q2 Earnings Snapshot (Associated Press Finance)
04:15PM	Nektar Therapeutics Reports Second Quarter 2024 Financial Results (PR Newswire)
Aug-01-24 06:00PM	Nektar to Announce Financial Results for the Second Quarter 2024 on Thursday, August 8, 2024, After Close of U.S.-Based Financial Markets (PR Newswire) -5.22% -5.51%
Jun-12-24 09:30AM	Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024 (PR Newswire)
May-30-24 06:00PM	Nektar Management to Present at Upcoming Investor Conferences (PR Newswire) -8.70%
May-10-24 04:41PM	Nektar Therapeutics (NASDAQ:NKTR) Q1 2024 Earnings Call Transcript (Insider Monkey) +10.00%
03:14PM	Nektar Therapeutics (NKTR) First Quarter 2024 Earnings Overview (GuruFocus.com)
11:33AM	Nektar's (NKTR) Q1 Earnings and Revenues Surpass Estimates (Zacks)
10:35AM	Q1 2024 Nektar Therapeutics Earnings Call (Thomson Reuters StreetEvents)
May-09-24 05:39PM	Nektar: Q1 Earnings Snapshot (Associated Press Finance)
04:15PM	Nektar Therapeutics Reports First Quarter 2024 Financial Results (PR Newswire)
06:00PM	Loading…
May-02-24 06:00PM	Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial Markets (PR Newswire) -5.99%
Apr-03-24 11:30AM	Nektar (NKTR) Up 7.5% Since Last Earnings Report: Can It Continue? (Zacks) +9.47%
Mar-25-24 10:00AM	DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-22-24 02:00PM	Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference (PR Newswire)
Mar-06-24 12:33PM	Nektar (NKTR) Begins Phase IIb Study Rezpeg in Alopecia Areata (Zacks)
Mar-05-24 10:07AM	Nektar (NKTR) Q4 Loss Wider Than Expected, Revenue Beat (Zacks)
09:13AM	Nektar Therapeutics (NASDAQ:NKTR) Q4 2023 Earnings Call Transcript (Insider Monkey)
09:00AM	Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata (PR Newswire)
07:19AM	Q4 2023 Nektar Therapeutics Earnings Call (Thomson Reuters StreetEvents)
Mar-04-24 05:30PM	Nektar Therapeutics (NKTR) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +15.38%
04:51PM	Nektar Therapeutics (NKTR) Reports Fiscal Year-End and Q4 2023 Results (GuruFocus.com)
04:42PM	Nektar: Q4 Earnings Snapshot (Associated Press Finance)
04:15PM	Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results (PR Newswire)
08:30AM	Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX (PR Newswire)
Feb-27-24 06:00PM	Nektar Management to Present at the TD Cowen 44th Annual Health Care Conference (PR Newswire) +11.94%
Feb-26-24 06:00PM	Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2023 on Monday, March 4, 2024, After Close of U.S.-Based Financial Markets (PR Newswire)
Feb-20-24 10:00AM	Will Nektar Therapeutics (NKTR) Report Negative Q4 Earnings? What You Should Know (Zacks) -6.78%
Jan-03-24 06:00PM	Nektar Management To Present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA (PR Newswire) -6.36%
Dec-11-23 06:00PM	Nektar and Collaborators Present Preclinical Data on NKTR-255 Combined with Obinutuzumab in Poster Presentation at the 65th American Society of Hematology (ASH) Annual Meeting (PR Newswire) -5.94%
Dec-07-23 11:31AM	Nektar (NKTR) Up 4% Since Last Earnings Report: Can It Continue? (Zacks)
Nov-09-23 08:39AM	Nektar Therapeutics (NASDAQ:NKTR) Q3 2023 Earnings Call Transcript (Insider Monkey) -5.00%
Nov-08-23 11:47AM	Nektar Therapeutics (NKTR) Incurs Wider-Than-Expected Q3 Loss (Zacks) -8.76%
Nov-07-23 05:28PM	Nektar: Q3 Earnings Snapshot (Associated Press Finance)
04:15PM	Nektar Therapeutics Reports Third Quarter 2023 Financial Results (PR Newswire)
Oct-31-23 06:00PM	Nektar to Announce Financial Results for the Third Quarter 2023 on Tuesday, November 7, 2023, After Close of U.S.-Based Financial Markets (PR Newswire)
Oct-26-23 10:02AM	Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-23-23 10:08AM	12 Best Penny Stocks to Buy Under $1 (Insider Monkey) -7.11%
Oct-13-23 08:30AM	Nektar Presents New Responder Data for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy, in Late-Breaking News Oral Presentation at 2023 EADV Congress (PR Newswire)
Oct-02-23 09:00AM	Nektar Therapeutics Announces Two Abstracts Accepted at EADV Congress 2023 for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy (PR Newswire)
Sep-27-23 09:00AM	Nektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluate NKTR-255 in Combination with C-TIL051 in Advanced Non-Small Cell Lung Cancer (PR Newswire)
Sep-14-23 07:54AM	Nektar (NKTR) Up on Positive New Data From Eczema Study (Zacks)
Sep-13-23 09:00AM	Nektar Therapeutics Announces Promising New Data from Phase 1b Study of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis (PR Newswire)
Sep-07-23 11:31AM	Why Is Nektar (NKTR) Down 37.1% Since Last Earnings Report? (Zacks)
Sep-06-23 06:00PM	Nektar Therapeutics to Host Virtual Investor & Analyst Event with Dermatology Experts on September 13th (PR Newswire)
Aug-17-23 07:02PM	RA Capital Management, L.P. Acquires Significant Stake in Nektar Therapeutics (GuruFocus.com) -6.26%
Aug-09-23 09:25AM	Nektar Therapeutics (NKTR) Q2 Loss Narrows, Sales Miss (Zacks) -8.94%
Aug-08-23 05:30PM	Nektar Therapeutics (NKTR) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:23PM	Nektar: Q2 Earnings Snapshot (AP Finance)
04:15PM	Nektar Therapeutics Reports Second Quarter 2023 Financial Results (PR Newswire)
11:08AM	Nektar Therapeutics sues Lilly for breach of contract around skin drug (American City Business Journals)
Aug-07-23 10:23AM	Nektar Therapeutics sues Eli Lilly over autoimmune disease treatment (Reuters) +91.51%
06:30AM	Nektar Announces Promising New and Corrected Rezpegaldesleukin Efficacy Data Which Were Previously Reported in 2022 and Incorrectly Calculated by Former Collaborator Eli Lilly & Company (PR Newswire)
Aug-01-23 06:00PM	Nektar to Announce Financial Results for the Second Quarter 2023 on Tuesday, August 8, 2023, After Close of U.S.-Based Financial Markets (PR Newswire)
Jul-24-23 03:48AM	Zoetis (ZTS) Moves 6.9% Higher: Will This Strength Last? (Zacks) -5.69%
Jul-16-23 08:49AM	Nektar Therapeutics (NASDAQ:NKTR) is largely controlled by institutional shareholders who own 70% of the company (Simply Wall St.)
Jun-12-23 06:00PM	Nektar Therapeutics to Participate in Fireside Chat at the Goldman Sachs 44th Annual Global Healthcare Conference (PR Newswire)
Jun-08-23 12:55PM	Investors Don't See Light At End Of Nektar Therapeutics' (NASDAQ:NKTR) Tunnel (Simply Wall St.)
11:31AM	Why Is Nektar (NKTR) Down 19.7% Since Last Earnings Report? (Zacks)
May-10-23 11:28AM	Nektar Therapeutics (NASDAQ:NKTR) Q1 2023 Earnings Call Transcript (Insider Monkey)
09:16AM	Nektar Therapeutics (NKTR) Q1 Earnings & Revenues Beat (Zacks)
May-09-23 06:45PM	Nektar Therapeutics (NKTR) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
05:41PM	Nektar: Q1 Earnings Snapshot (AP Finance)
04:15PM	Nektar Therapeutics Reports First Quarter 2023 Financial Results (PR Newswire)
May-08-23 09:29AM	Biotech Stocks' Q1 Earnings on May 9: NVAX, EBS & More (Zacks) -5.94%
May-04-23 10:00AM	Earnings Preview: Marinus Pharmaceuticals (MRNS) Q1 Earnings Expected to Decline (Zacks)
May-02-23 10:01AM	Will Nektar Therapeutics (NKTR) Report Negative Earnings Next Week? What You Should Know (Zacks)
Apr-27-23 08:30AM	Nektar Therapeutics Announces It Will Regain Full Rights to Rezpegaldesleukin (REZPEG, NKTR-358), a Novel, First-in-Class Selective Regulatory T-cell (Treg) Therapy in Clinical Development (PR Newswire)
Apr-19-23 08:38AM	Zacks.com featured highlights include Disney, Casey's General Stores, OpGen, Accelerate Diagnostics and Nektar Therapeutics (Zacks)
Apr-17-23 05:00PM	Nektar Therapeutics Announces Strategic Reprioritization and Cost Restructuring Plan (PR Newswire) +6.26% -5.67%
Apr-16-23 06:30AM	7 Sorry Pharma Stocks to Sell in April Before Its Too Late (InvestorPlace)
Apr-13-23 10:59AM	Here's Why You May Add Nektar (NKTR) Stock to Your Portfolio (Zacks) +10.16%
Apr-11-23 08:57AM	Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, KalVista Pharmaceuticals, Larimar Therapeutics, Nektar Therapeutics and Jounce Therapeutics (Zacks) +10.53%
Apr-10-23 10:07AM	5 Stocks to Buy as the Drug Industry Rebounds in 2023 (Zacks) +6.57%
Apr-02-23 08:27AM	We Think Nektar Therapeutics (NASDAQ:NKTR) Needs To Drive Business Growth Carefully (Simply Wall St.)
Mar-30-23 11:30AM	Why Is Nektar (NKTR) Down 51.9% Since Last Earnings Report? (Zacks) -12.42%
Mar-29-23 05:44PM	Crane Set to Join S&P MidCap 400; PacWest Bancorp to Join S&P SmallCap 600 (PR Newswire)
Mar-24-23 12:00PM	Nektar (NKTR) Upgraded to Buy: Here's Why (Zacks)
Mar-22-23 09:35AM	Down -69.13% in 4 Weeks, Here's Why You Should You Buy the Dip in Nektar (NKTR) (Zacks) -9.73%
Mar-14-23 03:43AM	Sage Therapeutics, Inc. (SAGE) Soars 9.6%: Is Further Upside Left in the Stock? (Zacks)
Feb-28-23 05:15PM	Nektar Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results (PR Newswire) +9.42%

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Zalevsky Jonathan	Chief R&D Officer	Nov 19 '24	Sale	1.01	7,785	7,863	243,019	Nov 20 08:37 PM
Wilson Mark Andrew	Chief Legal Officer	Nov 19 '24	Sale	1.01	6,407	6,471	218,856	Nov 20 08:36 PM
ROBIN HOWARD W	President & CEO	Nov 19 '24	Sale	1.01	16,278	16,441	832,080	Nov 20 08:36 PM
Zalevsky Jonathan	Officer	Nov 19 '24	Proposed Sale	1.01	7,785	7,878		Nov 19 04:10 PM
Wilson Mark Andrew	Officer	Nov 19 '24	Proposed Sale	1.01	6,407	6,483		Nov 19 03:28 PM
ROBIN HOWARD W	Officer	Nov 19 '24	Proposed Sale	1.01	16,278	16,472		Nov 19 03:17 PM
Zalevsky Jonathan	Chief R&D Officer	Aug 19 '24	Sale	1.28	6,866	8,788	250,804	Aug 20 09:15 PM
Wilson Mark Andrew	Chief Legal Officer	Aug 19 '24	Sale	1.28	5,651	7,233	225,263	Aug 20 09:15 PM
ROBIN HOWARD W	President & CEO	Aug 19 '24	Sale	1.28	14,881	19,048	848,358	Aug 20 09:14 PM
Wilson Mark Andrew	Officer	Aug 19 '24	Proposed Sale	1.28	5,651	7,211		Aug 19 04:13 PM
ROBIN HOWARD W	Officer	Aug 19 '24	Proposed Sale	1.28	14,881	18,990		Aug 19 04:03 PM
Zalevsky Jonathan	Officer	Aug 19 '24	Proposed Sale	1.28	6,866	8,762		Aug 19 03:45 PM
CHESS ROBERT	Director	Jun 14 '24	Sale	1.20	19,500	23,400	255,273	Jun 14 06:02 PM
ROBIN HOWARD W	President & CEO	May 17 '24	Sale	1.75	16,650	29,138	863,239	May 20 09:14 PM
Zalevsky Jonathan	Chief R&D Officer	May 17 '24	Sale	1.75	7,355	12,871	257,670	May 20 09:13 PM
Wilson Mark Andrew	Chief Legal Officer	May 17 '24	Sale	1.75	6,260	10,955	230,414	May 20 09:12 PM
Deep Track Capital, LP	10% Owner	May 10 '24	Sale	1.78	56,000	99,630	18,344,000	May 13 04:36 PM
Zalevsky Jonathan	Chief R&D Officer	Feb 20 '24	Sale	0.68	9,014	6,130	265,025	Feb 22 08:19 PM
Wilson Mark Andrew	Chief Legal Officer	Feb 20 '24	Sale	0.68	7,606	5,172	236,674	Feb 22 08:17 PM
ROBIN HOWARD W	President & CEO	Feb 20 '24	Sale	0.68	20,033	13,622	879,889	Feb 22 08:16 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NKTR

Nektar Therapeutics

Upgrade your FINVIZ experience